Investigational Site Number :2030002

Prague 14021

1 studies enrolling now · 10 studies all time

What they study most

Breast Cancer, Chronic Obstructive Pulmonary Disease, Heart Failure, Immune Thrombocytopenia, Neoplasm, Neoplasm Malignant, Non-small Cell Lung Cancer Metastatic, Polycystic Kidney, Autosomal Dominant, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus

Studies at this site

• Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment — Recruiting now
• Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS) — Running, not enrolling
• First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL — Completed
• Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer — Stopped early
• Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04) — Stopped early
• Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies — Stopped early
• A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients — Stopped early
• Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial) — Stopped early